A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 ...
Noom has launched a new Proactive Health GLP-1 Program focused on preventive health care. The program includes at-home testing of 17 biomarkers, behavioral support, and personalized GLP-1 microdosing ...
Orforglipron (LY3502970) is a small-molecule, non-peptide GLP-1RA designed for oral use. Compared to popular GLP-1RAs like semaglutide, orforglipron does not require injection or an absorption ...
Patients using GLP-1 agonists had a significantly lower hysterectomy rate over 2-year and 5-year follow-up. Women with nonmalignant uterine disease and a history of GLP-1 agonist and progestin ...
Share on Pinterest Research suggests that GLP-1 drugs likely have little to no effect on risk for obesity-related cancers. Image credit: James Manning – PA Images/Getty Images In 2022, about 2.5 ...
What if you lost weight and didn’t care — about anything?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results